Nanotechnology for Treating Coronary In-Stent Restenosis
Author Information
Author(s): Garry McDowell, Mark Slevin, Jerzy Krupinski
Primary Institution: Edge Hill University
Hypothesis
Can nanotechnology improve the treatment of coronary in-stent restenosis?
Conclusion
The study found that systemic nab-paclitaxel was well tolerated at doses below 70 mg/m2, with no major adverse cardiac events recorded.
Supporting Evidence
- The first human safety trial showed no significant adverse events at lower doses of nab-paclitaxel.
- Moderate neutropenia and sensory neuropathy were observed at higher doses.
- No major adverse cardiac events were recorded at 2 months post-treatment.
Takeaway
This study looks at using tiny particles to help prevent problems after heart stents are put in. It found that one type of tiny particle was safe for people.
Methodology
The study reviewed existing literature and discussed the first human safety trial of systemic nab-paclitaxel for in-stent restenosis.
Limitations
Most studies were conducted in animal models or outside the coronary circulation, limiting the relevance to human coronary in-stent restenosis.
Participant Demographics
The study involved 23 patients who received systemic treatment after stenting.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website